Background: DNA methylation is the commonest known epigenetic change that results in silencing of tumor suppressor genes. Promoter methylation of tumor suppressor genes has the potential for early detection of breast cancer. Aim: Aim is to examine the potential usefulness of blood based methylation specific polymerase chain reaction (MSP) of methylated DKK3 and RASSF1A genes in early detection of breast cancer. Method: Methylation status of DKK3 and RASSF1 was investigated in forty breast cancer patients, twenty fibroadenoma patients and twenty healthy ladies as control group using MSP. Results: Methylation of DKK3 promoter was found in 22.5% of breast cancer patients, while DKK3 methylation was absent in both fibroadenoma patients and control group. Similarly, methylation of RASSF1 promoter was found in 17.5% of breast cancer patients and in none of fibroadenoma and control group. Conclusion: Promoter methylation of DKK3 and RASSF1 was found in breast cancer patients while absent in control group suggesting that tumorspecific methylation of the two genes (DKK3 and RASSF1A) might be a valuable biomarker for the early detection of breast cancer. 
Introduction
The World Health Organization has ranked breast cancer (BC) as the most common type of cancer among women. BC remains the most invasive cancer and the first leading cause of cancer related deaths among women worldwide [1] .
Survival rates vary greatly worldwide with the lowest rates in developing countries. These low rates can be explained mainly by the lack of early detection programs as well as inadequate diagnosis and shortage of treatment facilities, resulting in a high proportion of women presenting with late-stage disease [2] . Diagnosis of BC in early stage has a 5-year survival rate up to 98% [3] .
Mammography has become the gold standard tool for BC screening as it is sensitive enough to detect ductal carcinoma in situ (DCIS). However, it has many limitations to stand alone. The worst limitation of mammography is that clinically occult early-stage BC is often similar in appearance to a benign breast lesion, resulting in unnecessary subsequent biopsies [4, 5] . Therefore, non-invasive sensitive tests are required to complement mammography or even stand alone as a primary screening and diagnostic tool for early detection of BC. The epigenetic markers fulfill these criteria such as methylated DNA and miRNAs since changes in their levels have been associated with tumor burden and malignant progression [6] .
Determination of promoter methylation of tumor-suppressor genes in the DNA of blood is a rapidly growing research field in cancer detection. The principle of DNA methylation markers for early BC discovery is based on evidence that growing tumors release significant amounts of circulating DNA into bloodstream through cellular necrosis, apoptosis, or spontaneous release of DNA from primary and metastatic tumors [7] .
DKK3 gene is a member of the human Dickkopf (Dkk) family (WNT signaling pathway inhibitors) located on short arm of chromosome 11 p15.3. The transcript length equals to 566 bps [8, 9] . DKK3 expression is frequently suppressed by its promoter methylation in BC [10] .
Additionally, RASSF1A gene is a Ras association domain family member 1, which is located on short arm of chromosome 3 p21.3. Methylation of the RASSF1A promoter region is the most frequently described epigenetic event associated with the development of human cancer. It occurs early in the carcinogenesis of BC 
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Therefore, in the present study, two tumor-suppressor genes (DKK3 and RASSF1A) were investigated among Egyptian females with BC, and comparing the results to those of fibroadenoma patients (the most common benign breast disease) [13] and healthy controls using methylation specific polymerase chain reaction (MSP).
Subjects and methods

Patients
This study was carried out on 80 females; forty BC patients, twenty fibroadenoma patients and twenty matched age healthy ladies as control group. The study was approved by local ethics committee. All BC patients undergo full history taking, clinical examination, mammography and prognostic markers (progesterone receptors [PR], estrogen receptors [ER] , and human epidermal growth factor receptor-2 [Her-2/neu]). The control group was free of family history of BC. Clinicopathological parameters were investigated in BC patients including: possible family history of BC, the histopathology of tumor, tumor stage, lymph nodes involvement and BC hormonal assay (ER, PR and Her-2/neu).
Determination of the methylation status of DKK3 and RASSF1A promoters using (MSP)
Firstly, DNA was extracted from blood using QIAGEN total DNA purification kit (QIAamp DNA Blood Mini Kit), QIAGEN, Germany. The extracted DNA was bisulfite converted using the EZ DNA methylation kit (Zymo Research, Orange, CA, USA). The methylation status of the promoter of DKK3 and RASSF1A genes was determined qualitatively by MSP [14] . Briefly, the bisulfite-converted DNA was amplified using primer sets specific for both unmethylated and methylated promoter sequences of DKK3 and RASSF1A genes. 25 ll PCR mix containing 2.5 ll bisulfite-modified DNA, 1 ll forward primer, 1 ll reverse primer, 12.5 ll of Epitect MSP master mix and 8 ll RNase free water was prepared. The previous mix was subjected to 95°C for 10 min followed by 40 cycles of 94°C for 30 s, primer annealing at 63°C for DKK3 gene and at 55°C for RASSF1A gene for 30 s, 72°C for 30 s, and a final extension step at 72°C for 10 min. MSP primer sequences and annealing temperature are listed in Table 1 . PCR amplicons were electrophoresed on 2% agarose gels and visualized using transilluminator ultraviolet light. Universal methylated and unmethylated control (Epi Tect Control DNA Set, Qiagen, Germany) were included in each run. The sample is considered to have methylated or unmethylated gene allele depending on the primer pairs used. Consequently, sample is considered methylated when band appears only with methylated primers or unmethylated when band appears only with unmethylated primers) or hemimethylated if bands were appeared with both methylated and unmethylated primers; meaning that the patient has both alleles: methylated and unmethylated.
Statistical methods
Data analysis was performed using the software package SPSS version 10.0 (SPSS, Inc., Chicago, IL, USA). ANOVA was used to analyze differences between groups. The chi-squared test is used to determine whether there is a significant difference between the expected frequencies and the observed frequencies in one or more categories. Results were considered significant if the p value was less than 0.05.
Results
The age of BC patients and healthy controls ranged from 28 to 61 years, and from 23 to 60 years respectively. However, fibroadenoma patients' age ranged from 21 to 54 years. The age of fibroadenoma patients was significantly low with p < 0.001, that in line with the fact that fibroadenoma is a disease of young ladies [13] . Comparing the menopausal status between the studied groups revealed that 60% of BC patients and controls were in premenopausal state, while the rest (40%) were in post-menopausal period with no significant difference between both groups. However, most of fibroadenoma group were in pre-menopausal state (90%) with significant difference versus BC and controls (p < 0.001).
Clinicopathological characteristics of BC
Regarding BC patients, about 37.5% of patients had positive family history of BC. Positive ER were encountered among 57.5% of patients, while positive PR were encountered among 30% of cases. On the other hand, Her2/neu receptors were negative in more than four fifths of cases (92.5%) ( Table 2) . Furthermore, metastasis were found in 15% of patients varing between bone and liver metastasis, while lymph nodes involvement were found in 40% of cases. Regarding the stage of the tumor, 72.5% of patients were stage II, 12.5% were stage III and about 15% of cases were stage IV. The histopathological findings revealed that the majority of BC (95%) had infiltrating ductal carcinoma, while 5% had infiltrating lobular carcinoma (Table 2 ).
Assessment of DKK3 and RASSF1A promoter methylation using MSP
Next, DKK3 and RASSF1A promoter methylation were assessed in the three studied groups. DKK3 and RASSF1A methylation were present only in BC patients [DKK3 in 9 patients (22.5%), RASSF1A in 7 patients, (17.5%)]. Either DKK3 or RASSF1A methylation was not detected in fibroadenoma or controls (Table 3) .
Then, we studied potential associations between DKK3 and RASSF1A promoter methylation and the clinicopathological parameters (Table 4) . Only significant correlation between DKK3 promoter methylation and distant metastasis was identified (p = 0.041). No significant correlation was detected between RASSF1A methylation and any of the studied parameters e.g. family history, tumor stage, distant metastasis (unpublished data). 
Correlation between DKK3 and RASSA1 promoter methylation in BC patients
Methylation of DKK3 was significantly associated with methylation of RASSA1 (chi-square test-p = 0.0005). Both gene promoters were methylated in 6 patients (15%) and were unmethylated in 18 patients (45%). One patient was DKK3 methylated-RASSA1 unmethylated (2.4%) and one patient was DKK3 unmethylated-RASSA1 methylated (2.4%)
Determination which gene is better as blood-based BC test with qualitative MSP
Initially, the sensitivity and specificity of each gene was determined. Sensitivity of DKK3 methylation alone in BC was 22.5% (9 out of 40 patients were methylated) with specificity 100% as all fibroadenoma patients and controls were methylation negative. Besides, RASSF1A methylation has sensitivity of 17.5% (7 out of 40 patients were methylated) with specificity 100% as the fibroadenoma and controls showed no methylation (Table 5 ). Combining both of DKK3 and RASSF1A methylation revealed an improvement in the sensitivity of the panel up to 40% (16 out of 40 patients) for the detection of BC and a specificity of 100% (20 out of 20 were negative for methylation) in fibroadenoma and controls (Table 5 ).
Discussion
In the present study we evaluated the performance of the promoter methylation of two tumor suppressor genes i.e. DKK3 and RASSF1A. Each gene has different role in BC pathogenesis e.g. DKK3 is WNT signaling pathway inhibitor [8, [15] [16] [17] , while RASSF1A regulates the apoptotic process. Therefore, promoter methylation followed by silencing of the previous genes would assist in the disease carcinogensis. Here, for the first time we used qualitative MSP Table 3 Comparison between the three studied groups according to the MSP results of DKK3 and RASSF1 genes. for DKK3 and RASSF promoter methylation assay in the blood of Egyptian BC patients. To see the potential usefulness of both genes in BC, we compared the results to those of both genes in most common benign breast disease (fibroadenoma) and in healthy controls. Also, blood was used as non-invasive sample to investigate the suitability of this technique in different stages of BC patients. DKK3 promoter methylation was not found in either fibroadenoma patients or controls. However, nine out of forty BC patients (22.5%) showed methylation of DKK3. Correlating the clinicopathological parameters with DKK3 promoter methylation revealed no association with any of the previous parameters except distant metastasis (p = 0.041). Previously, DKK3 methylation showed significant correlation with poor overall patients [18] . That might indicate the useful prognostic role of DKK3 methylation in predicting patient survival. Additionally, downregulation of DKK3 expression was detected in highly aggressive basal BC subtype [19] .
On the other hand, methylated RASSF1A was detected in 7 patients out of the forty BC patients (17.5%), without any methylation detection in fibroadenoma patients or controls. RASSF1A promoter methylation was previously detected in BC tissues and BC cell lines [20] , in plasma DNA of BC patients [21] , also in serum DNA of BC patients [22, 23] . RASSF1A showed different sensitivity and specificity in different studies which is related most probably to number of the samples included. For instance, in a big cohort study of 261 BCE serum, 112 paired BC tissue and 237 of cancer free individuals showed high sensitivity of RASSF1A methylation (47%) with quite low specificity (74%), which may indicate that RASSF1A alone is not highly specific [15] . Opposite to DKK3, RASSF1A did not show significant correlation with distant metastasis. However, this does not exclude the association of RASSF1A methylation with tumor progression and metastasis [24] . Given the frequencies of RASSF1A methylation in cancer, RASSF1A was included in our study besides DKK3 in a panel for detection of BC. Such addition has raised the sensitivity to be 40% comparing to sensitivity of applying each gene alone e.g. 22.5% using DKK3 and 17.5% using RASSF1A.
The epigenetic changes in cancer are very heterogeneous [25] , so using panels of more than one gene will improve the screening procedures. Therefore, promoter methylation of the DKK3/RASSF1A genes combination allowed significant discrimination of BC blood from benign breast disease and control groups with sensitivity higher than using each one alone. This panel represents a simple and non-invasive blood based test that can complement mammography in early detection of BC.
